Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

• Main Authors: F. Fischetti (Author), L.M. Bambara (Author), A. Carletto (Author), M. Cutolo (Author), P. Sarzi-Puttini (Author), R. Pellerito (Author), C. Fabro (Author), E. Pontarini (Author), M.A. Cimmino (Author), P. Morassi (Author), F. Atzeni (Author), M. Saracco (Author), M. Manfredi (Author), M. Benucci (Author), S. Lombardi (Author), L. Quartuccio (Author), M. Fabris (Author), F. Curcio (Author), E. Tonutti (Author), S. De VIta (Author)
• Format: Book
• Published: PAGEPress Publications, 2011-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Several studies demonstrated the efficacy of the B-cell depletion therapy with rituximab (RTX) in RA patients, including those unresponsive to anti- TNF therapy, underlying the important role of B cells in this disease (1-5). Several recent papers have demonstrated a differential effects of RTX in depleting B-cells and blocking plasma cell generation at the synovial and at the bone marrow level (7-9). This differential effect may explain why among patients who respond to RTX, some relapse while others show a very prolonged response, independently from the reappearance of B-cells in the peripheral blood (6). However, the efficacy of RTX may also depend on the individual genetic predisposition. At this regard, very few data were produced by now.

Item Description

10.4081/reumatismo.2010.253
0048-7449
2240-2683